{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:04:10Z","timestamp":1749463450029},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,2]]},"DOI":"10.7759\/cureus.34568","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T02:21:02Z","timestamp":1675390862000},"source":"Crossref","is-referenced-by-count":2,"title":["Adalimumab-Induced Lupus Serositis: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Sandy","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lafian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tandis","family":"Mahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrnaz","family":"Hojjati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165\/11588500-000000000-00000","article-title":"Drug-induced lupus erythematosus: incidence, management and prevention","volume":"34","author":"Chang C","year":"2011","unstructured":"Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011, 34:357-74. 10.2165\/11588500-000000000-00000","journal-title":"Drug Saf"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals M","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, et al.. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007, 86:242-51. 10.1097\/MD.0b013e3181441a68","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors - state of knowledge","volume":"10","author":"Lis K","year":"2014","unstructured":"Lis K, Kuzawi\u0144ska O, Ba\u0142kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014, 10:1175-85. 10.5114\/aoms.2014.47827","journal-title":"Arch Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff MH","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006, 65:889-94. 10.1136\/ard.2005.043166","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314523871","article-title":"Drug-induced lupus: including anti-tumour necrosis factor and interferon induced","volume":"23","author":"Ara\u00fajo-Fern\u00e1ndez S","year":"2014","unstructured":"Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus. 2014, 23:545-53. 10.1177\/0961203314523871","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt M","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Lo\u00ebt X, et al.. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005, 7:R545-51. 10.1186\/ar1715","journal-title":"Arthritis Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3884-2","article-title":"Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature","volume":"37","author":"Shovman O","year":"2018","unstructured":"Shovman O, Tamar S, Amital H, Watad A, Shoenfeld Y. Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature. Clin Rheumatol. 2018, 37:563-8. 10.1007\/s10067-017-3884-2","journal-title":"Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04871.x","article-title":"TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists","volume":"50","author":"Williams VL","year":"2011","unstructured":"Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011, 50:619-25. 10.1111\/j.1365-4632.2011.04871.x","journal-title":"Int J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals M","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010, 9:188-93. 10.1016\/j.autrev.2009.10.003","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg MC","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725. 10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901206010315","article-title":"Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus","volume":"6","author":"Almoallim H","year":"2012","unstructured":"Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus. Open Rheumatol J. 2012, 6:315-9. 10.2174\/1874312901206010315","journal-title":"Open Rheumatol J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4065\/84.11.979","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter DA","year":"2009","unstructured":"Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009, 84:979-84. 10.4065\/84.11.979","journal-title":"Mayo Clin Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131680-adalimumab-induced-lupus-serositis-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:32Z","timestamp":1707508172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131680-adalimumab-induced-lupus-serositis-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.34568","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}